{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:26:15Z","timestamp":1760235975023,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100003887","name":"International Myeloma Foundation","doi-asserted-by":"publisher","award":["xxx"],"award-info":[{"award-number":["xxx"]}],"id":[{"id":"10.13039\/100003887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG2018-ID22131"],"award-info":[{"award-number":["IG2018-ID22131"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006694","name":"Associazione Italiana Contro le Leucemie Linfomi e Mieloma","doi-asserted-by":"publisher","award":["XXX"],"award-info":[{"award-number":["XXX"]}],"id":[{"id":"10.13039\/501100006694","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FON.CA.NE.SA","award":["XXX"],"award-info":[{"award-number":["XXX"]}]},{"name":"Research Funding for University of Catania","award":["xxx"],"award-info":[{"award-number":["xxx"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background Myeloid dysfunction is an emerging hallmark of microenvironment changes occurring in multiple myeloma (MM). Our previous work showed that Fc\u03b3RI\/CD64 overexpression in neutrophils of newly diagnosed MM patients is associated to inferior outcomes, reduced oxidative bursts and phagocytosis, with an increased risk of bacterial infections. Pomalidomide is a novel immune-modulatory drug approved for relapsed\/refractory patients (RRMM), with drug-related neutropenia as major limitation to treatment. Patients and methods Herein, we describe a prospective analysis of 51 consecutive RRMM patients treated with pomalidomide and dexamethasone (PomDex) from March 2015 through December 2016, associated with secondary prophylaxis with filgrastim (G-CSF) in case of neutrophil count &lt;1500 cells\/\u03bcL. Neutrophil function was investigated by flow cytometry, including the phagocytosis, oxidative bursts, and median fluorescence intensity of Fc\u03b3RI-CD64. Controls included a group of newly diagnosed symptomatic MM (NDMM), asymptomatic (smoldering myeloma, MGUS) and healthy subjects referred to our Center in the same time-frame. Results Compared to controls, RRMM neutrophils had higher expression of Fc\u03b3RI\/CD64 and lower phagocytic activity and oxidative bursts. We maintained median leukocyte counts higher than 3.5 \u00d7 109\/L for 6 cycles, and median neutrophil counts higher than 1.5 \u00d7 109\/L, with only 6 (11%) patients developing grade 3\u20134 infections, without pomalidomide dose reduction. After 4 cycles of PomDex, Fc\u03b3RI\/CD64 was further increased in neutrophils, and phagocytic activity and oxidative bursts recovered independently from filgrastim exposure and the quality of hematological responses. Similarly, in NDMM patients, lenalidomide but not bortezomib upregulated Fc\u03b3RI\/CD64 expression, improving phagocytic activity and oxidative bursta as tested in vitro. Conclusions Our combined biological and clinical data provide new information on the ability of pomalidomide and lenalidomide to modulate the functional activity of neutrophils, despite their chronic activation due to Fc\u03b3RI\/CD64 overexpression.<\/jats:p>","DOI":"10.3390\/biomedicines9101455","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T09:33:02Z","timestamp":1634117582000},"page":"1455","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lenalidomide and Pomalidomide Improve Function and Induce Fc\u03b3RI\/CD64 in Multiple Myeloma Neutrophils"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-4433","authenticated-orcid":false,"given":"Alessandra","family":"Romano","sequence":"first","affiliation":[{"name":"Dipartimento di Chirurgia e Specialit\u00e0 Medico-Chirurgiche, Universit\u00e0 degli Studi di Catania, 95123 Catania, Italy"},{"name":"Division of Hematology, AOU \u201cPoliclinico\u2014Vittorio Emanuele\u201d, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9978-2908","authenticated-orcid":false,"given":"Nunziatina Laura","family":"Parrinello","sequence":"additional","affiliation":[{"name":"Division of Hematology, AOU \u201cPoliclinico\u2014Vittorio Emanuele\u201d, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Parisi","sequence":"additional","affiliation":[{"name":"Division of Hematology, AOU \u201cPoliclinico\u2014Vittorio Emanuele\u201d, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Del Fabro","sequence":"additional","affiliation":[{"name":"Division of Hematology, AOU \u201cPoliclinico\u2014Vittorio Emanuele\u201d, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1648-7979","authenticated-orcid":false,"given":"Angelo","family":"Curtopelle","sequence":"additional","affiliation":[{"name":"Division of Hematology, AOU \u201cPoliclinico\u2014Vittorio Emanuele\u201d, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Leotta","sequence":"additional","affiliation":[{"name":"Division of Hematology, AOU \u201cPoliclinico\u2014Vittorio Emanuele\u201d, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Conticello","sequence":"additional","affiliation":[{"name":"Division of Hematology, AOU \u201cPoliclinico\u2014Vittorio Emanuele\u201d, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[{"name":"Dipartimento di Chirurgia e Specialit\u00e0 Medico-Chirurgiche, Universit\u00e0 degli Studi di Catania, 95123 Catania, Italy"},{"name":"Division of Hematology, AOU \u201cPoliclinico\u2014Vittorio Emanuele\u201d, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"198539","DOI":"10.1155\/2014\/198539","article-title":"Immunological dysregulation in multiple myeloma microenvironment","volume":"2014","author":"Romano","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14737159.2018.1470929","article-title":"PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy","volume":"18","author":"Romano","year":"2018","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/s41598-020-58859-x","article-title":"High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling","volume":"10","author":"Romano","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3324\/haematol.2011.054015","article-title":"Monoclonal gammopathy of undetermined significance and risk of infections: A population-based study","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1172\/JCI88169","article-title":"Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression","volume":"128","author":"Kawano","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019004537","article-title":"Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma","volume":"136","author":"Perez","year":"2020","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"85764","DOI":"10.18632\/oncotarget.7969","article-title":"Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)","volume":"7","author":"Giallongo","year":"2016","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3389\/fimmu.2019.01958","article-title":"Expression, Role, and Regulation of Neutrophil Fc\u03b3 Receptors","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9561350","DOI":"10.1155\/2019\/9561350","article-title":"Neutrophil-derived MRP14 supports plasma cell commitment and protects myeloma cells from apoptosis","volume":"2019","author":"Zhao","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2015.10.040","article-title":"Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy","volume":"371","author":"Ramachandran","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.intimp.2006.03.001","article-title":"The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64","volume":"6","author":"McCarthy","year":"2006","journal-title":"Int. Immunopharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","article-title":"Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma","volume":"116","author":"Calabrese","year":"2010","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2217\/fon-2016-0368","article-title":"Pomalidomide experience: An effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma","volume":"13","author":"Conticello","year":"2017","journal-title":"Future Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Parisi, M.S., Leotta, S., Romano, A., Fabro, V.D., Martino, E.A., Calafiore, V., Giubbolini, R., Markovic, U., Leotta, V., and Di Giorgio, M.A. (2019). Clinical benefit of long-term disease control with pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients. J. Clin. Med., 8.","DOI":"10.3390\/jcm8101695"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/ejh.13106","article-title":"The efficacy and safety of pomalidomide in relapsed\/refractory multiple myeloma in a \u201creal-world\u201d study: Polish Myeloma Group experience","volume":"101","author":"Charlinski","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: A randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/leu.2014.60","article-title":"Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma","volume":"28","author":"Dimopoulos","year":"2014","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"Lhermitte","year":"2012","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-5793(96)00453-X","article-title":"Granulocyte colony-stimulating factor induces the binding of STAT1 and STAT3 to the IFNgamma response region within the promoter of the Fc(gamma)RI\/CD64 gene in human neutrophils","volume":"386","author":"Bovolenta","year":"1996","journal-title":"FEBS Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood.V78.4.885.885","article-title":"Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor","volume":"78","author":"Repp","year":"1991","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"84889","DOI":"10.18632\/oncotarget.20031","article-title":"Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects","volume":"8","author":"Manukyan","year":"2017","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s001090000107","article-title":"Differentiation of polymorphonuclear neutrophils in patients with systemic infections and chronic inflammatory diseases: Evidence of prolonged life span and de novo synthesis of fibronectin","volume":"78","author":"Wagner","year":"2000","journal-title":"J. Mol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.tube.2018.06.010","article-title":"Neutrophil CD64, TLR2 and TLR4 expression increases but phagocytic potential decreases during tuberculosis","volume":"111","author":"Das","year":"2018","journal-title":"Tuberculosis"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Puglisi, F., Parrinello, N.L., Giallongo, C., Cambria, D., Camiolo, G., Bellofiore, C., Conticello, C., Del Fabro, V., Leotta, V., and Markovic, U. (2019). Plasticity of high-density neutrophils in multiple myeloma is associated with increased autophagy via STAT3. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20143548"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/ejh.12903","article-title":"Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis","volume":"99","author":"Moreau","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00277-017-3191-7","article-title":"Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: Is current clinical practice adequate?","volume":"97","author":"Leleu","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1634\/theoncologist.2014-0073","article-title":"The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: Summary of the scientific assessment of the committee for medicinal products for human use","volume":"20","author":"Hanaizi","year":"2015","journal-title":"Oncologist"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3324\/haematol.2015.125864","article-title":"Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed\/refractory multiple myeloma","volume":"100","author":"Miguel","year":"2015","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s12185-018-2416-4","article-title":"Pomalidomide with or without dexamethasone for relapsed\/refractory multiple myeloma in Japan: A retrospective analysis by the Kansai Myeloma Forum","volume":"107","author":"Kuroda","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/ejh.13039","article-title":"Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma","volume":"100","author":"Gueneau","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e20514","DOI":"10.1200\/JCO.2020.38.15_suppl.e20514","article-title":"Pegfilgrastim versus filgrastim in the supportive care of heavily pretreated multiple myeloma in treatment with pomalidomide-dexamethasone","volume":"38","author":"Cerchione","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E232","DOI":"10.1002\/ajh.25858","article-title":"Phase I\/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"95","author":"Manasanch","year":"2020","journal-title":"Am. J. Hematol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/10\/1455\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:12:28Z","timestamp":1760166748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/10\/1455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["biomedicines9101455"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9101455","relation":{},"ISSN":["2227-9059"],"issn-type":[{"type":"electronic","value":"2227-9059"}],"subject":[],"published":{"date-parts":[[2021,10,13]]}}}